SGMT
NASDAQ · Biotechnology
Sagimet Biosciences Inc-A
$9.34
-0.60 (-6.04%)
Open$9.90
Previous Close$9.94
Day High$9.93
Day Low$9.30
52W High$11.45
52W Low$4.50
Volume—
Avg Volume1.20M
Market Cap561.10M
P/E Ratio—
EPS$-1.28
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
-67.9% upside
Current
$9.34
$9.34
Target
$3.00
$3.00
$2.20
$3.00 avg
$3.42
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 28.61M | 29.26M | 29.39M |
| Net Income | 3.39M | 4.16M | 4.24M |
| Profit Margin | 11.8% | 14.2% | 14.4% |
| EBITDA | 5.59M | 5.60M | 5.84M |
| Free Cash Flow | 4.74M | 2.94M | 4.50M |
| Rev Growth | +24.7% | +14.4% | -5.6% |
| Debt/Equity | 0.41 | 0.48 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |